Overview

A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

Status:
Not yet recruiting

Trial end date:
2031-10-27

Target enrollment:

Participant gender:

Summary

This is a Phase 3, double-blind, randomized, placebo-controlled, multicenter study of parsaclisib plus BR versus placebo plus BR as first-line treatment of participants with newly diagnosed MCL.

Phase:

Phase 3

Details

Lead Sponsor:

Incyte Corporation

Treatments:

Bendamustine Hydrochloride
Rituximab